Business Context and Reporting Period
This Form 6-K filing by MDxHealth SA covers the month of November 2023. The report details significant corporate governance actions, specifically amendments to the Company's Articles of Association regarding capital structure and stock exchange listing status.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate structural changes rather than financial performance.
Material Changes
- Capital Increase: On October 20, 2023, the Company amended its Articles of Association to account for a capital increase of 2,500,000 new shares.
- De-Listing Approval: On November 3, 2023, shareholders approved an amendment to Article 9 of the Articles of Association to allow for the de-listing of ordinary shares from Euronext Brussels.
- Shareholder Action: These changes were ratified at an extraordinary general shareholders' meeting held on November 3, 2023.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future operations, or specific risk factors beyond the structural changes noted. The primary contingency is the execution of the de-listing from Euronext Brussels following shareholder approval.
Investor Verification Checklist
- Verify the effective date and completion status of the de-listing from Euronext Brussels.
- Confirm the final issuance and settlement details of the 2,500,000 new shares.
- Review the attached Exhibit 3.1 for the full text of the amended Articles of Association.
- Check for subsequent filings regarding the Company's trading status post-de-listing.